VEGFR

VEGF receptors are receptors for vascular endothelial growth factor (VEGF). There are three main subtypes of VEGFR, numbered 1, 2 and 3. Also, they may be membrane-bound (mbVEGFR) or soluble (sVEGFR), depending on alternative splicing.

Cat. No.	Product name	CAS No.	Purity
T6730	WAY-600	1062159-35-6	99.63%
T6730	WAY-600 is a potent, ATP-competitive and selective inhibitor of mTOR with IC50 of 9 nM; blocks mTORC1/P-S6K(T389) and mTORC2/P-AKT(S473) but not P-AKT(T308); sel...
T22755	(E)-FeCP-oxindole	884338-18-5	99.62%
T22755	(E)-FeCP-oxindole is an inhibitor of VEGFR2 with IC50 of 214 nM.
T0093L	Sorafenib	284461-73-0	99.61%
T0093L	Sorafenib (Bay 43-9006) is a multikinase inhibitor that inhibits Raf-1, B-Raf, VEGFR2, VEGFR3, VEGFR4, PDGFRβ, FLT3, c-Kit, and others (IC50=6/22/90/15/20/20/57/...
T2586	Cabozantinib	849217-68-1	99.59%
T2586	Cabozantinib (XL184) is a multi-targeted tyrosine kinase receptor inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt3 (IC50=0.035/1.3/4.6/7/11.3 nM). Caboz...
T1948	AZD4547	1035270-39-3	99.56%
T1948	AZD4547, a new-type specific FGFR inhibitor, targets for FGFR1/2/3 (IC50: 0.2/2.5/1.8 nM in cell-free assays).
T15454	GW843682X	660868-91-7	99.56%
T15454	GW843682X (GW843682) is a selective and ATP-competitive inhibitor of PLK1 and PLK3 (IC50s = 2.2 nM and 9.1 nM).
T5466	Tyrosine kinase-IN-1	705946-27-6	99.55%
T5466	Tyrosine kinase-IN-1 is a multi-targeted tyrosine kinase inhibitor（KDR, Flt-1, FGFR1 and PDGFRα with IC50s of 4nM, 20nM, 4nM, 2 nM ,respectively）
T2906	Tanshinone IIA	568-72-9	99.54%
T2906	Tanshinone IIA (Tanshinone B)(Tanshinone B) is the diterpene quinone in Danshen, which is utilized in the treatment of cardiovascular and inflammatory.
T3980	Su1498	168835-82-3	99.54%
T3980	Su1498 (Tyrphostin SU 1498) is a selective inhibitor of the receptor tyrosine kinase VEGF receptor 2 (VEGFR2, aka FLK1; IC50 = 700 nM), having negligible activit...
T72924	VEGFR-3-IN-1	2756668-73-0	99.52%
T72924	VEGFR-3-IN-1 is a novel potent and selective VEGFR3 inhibitor with an IC50 of 110.4 nM.VEGFR-3-IN-1 possesses antitumor activity, inactivates the VEGFR3 signalin...
T9052	XL092	2367004-54-2	99.51%
T9052	XL092 (JUN04542) is an Axl Mer cMet KDR inhibitor for the treatment of Axl and Mer receptor tyrosine kinase- dependent disorders.
T22431	SU5204	186611-11-0	99.5%
T22431	SU5204 (3-[(2-Ethoxyphenyl)methylidene]-1H-indol-2-one), an analogue of SU5025, pharmacologically inhibits VEGFR2(IC50s of 4 and 51.5 μM for FLK-1 (VEGFR-2) and ...
T4425	JK-P3	942655-44-9	99.5%
T4425	JK-P3 is a pyrazole-based inhibitor of VEGFR-2 (IC50: 7.8 μM). JK-P3 inhibits FGFR 1/3 kinase activity in vitro, but has no effect on FGFR signaling in cell-base...
T1792L	Regorafenib monohydrate	1019206-88-2	99.47%
T1792L	Regorafenib Monohydrate is a novel oral multikinase inhibitor with IC50 values of 13, 4.2, 46, 22, 7, 1.5, 2.5, 28, 19 nM for VEGFR1, murine VEGFR2, murine VEGFR...
TN1853	Lariciresinol	27003-73-2	99.46%
TN1853	Lariciresinol is an enterolignan precursor, it possesses fungicidal activities by disrupting the fungal plasma membrane and therapeutic potential as a novel anti...
T0263	Chloropyramine hydrochloride	6170-42-9	99.45%
T0263	Chloropyramine hydrochloride (Alergosan) is a histamine receptor H1 antagonist.
T12145L	N-Desethylsunitinib hydrochloride	1261432-05-6	99.42%
T12145L	N-Desethylsunitinib hydrochloride is a major and pharmacologically active metabolite of sunitinib, which is potent, ATP-competitive VEGFR, PDGFRβ, and KIT inhibi...
T5475	ZD-4190	413599-62-9	99.42%
T5475	ZD-4190 is a compound that inhibits both the vascular endothelial growth factor receptor 2 (VEGFR2) and the epidermal growth factor receptor (EGFR) signaling pat...
T3476	JI-101	900573-88-8	99.41%
T3476	JI-101 (CGI-1842) is an oral multi-kinase inhibitor that targets vascular endothelial growth factor receptor type 2 (VEGFR-2), platelet derived growth factor rec...
T3S0153	Xanthatin	26791-73-1	99.39%
T3S0153	1. Xanthatin has cytotoxic activity. 2. Xanthatin has antibacterial and antifungal activies against MRSA. 3. Xanthatin may have therapeutic potential against NSC...